



Date: September 22, 2014
FOR IMMEDIATE RELEASE

CONTACT: Michelle McAdam
Chronic Communications
michelle@chronic-comm.com
(310) 902-1274

New Osmotic Technology to Treat Painful Sinus Infections Shows Excellent Results at One Year

*Innovative Vent-Os™ Sinus Dilation System Now Available in United States to Comfortably Treat
Sinusitis in Doctor's Office*

PALO ALTO, Calif. – September 22, 2014 – A new clinical study demonstrated that the [Vent-Os™ Sinus Dilation System](#) can unblock sinus passages using osmosis and maintain them for at least a year, resolving the debilitating symptoms of [sinusitis](#). The study was presented Saturday at the Annual Meeting of the American Rhinologic Society in Orlando, Florida. The Vent-Os procedure, developed by [SinuSys™ Corporation](#), is designed to easily and comfortably treat sinusitis in a doctor's office without surgery or repeated rounds of potentially harmful antibiotics and steroids.

The clinical study encompassed 34 sinusitis patients that were treated at five sites. At one year, 93 percent of sinuses were visibly clear and functional in the 27 patients available for evaluation.

The FDA-cleared Vent-Os procedure is typically performed in a doctor's office under topical or local anesthesia. It incorporates proprietary osmotic technology into a tiny capsule – the size of a grain of rice - which is inserted into the sinus opening and absorbs the body's natural fluids to slowly expand over approximately 60 minutes. After expansion, the capsule is gently removed and the patient is free to leave immediately.

“Opening up the sinus passage is an important factor in reducing or eliminating the often debilitating symptoms of sinusitis,” said Peter J. Catalano, MD, FACS, Chief of Otolaryngology, St. Elizabeth's Medical Center, Boston, MA, and a clinical investigator for the study. “The Vent-Os procedure could be an ideal option for sinusitis sufferers whose symptoms are not severe enough to warrant surgery but who suffer the poor quality of life and health risks associated with repetitive or failed use of antibiotics and steroids.”

Affecting 31 million Americans each year, sinusitis is more prevalent than heart disease and asthma, and has a greater impact on patients' quality of life than chronic back pain or

congestive heart failure. The often debilitating symptoms include severe facial pain, pressure and swelling, headache, congestion, dental pain, dizziness, sore throat and fatigue.

Most patients see their isolated cases of sinusitis resolved with medication. However, many experience sinusitis regularly over time, and while medication may resolve the symptoms each time, they continue to return. This continuous use of antibiotics and steroids to treat recurrent disease can create drug resistance or other health issues for patients. Those suffering from allergies or asthma may be more susceptible to sinus infections as the pre-existing inflammation may trap bacteria in the sinus, creating an optimal environment for infection.

For more information about the Vent-Os procedure, visit www.sinustreatmentinfo.com.

About SinuSys Corp.

SinuSys Corp. (www.sinusys.com) develops medical device therapies to improve the health of millions of patients suffering from sinusitis worldwide. The company's proprietary self-expanding, osmotic technology is designed to be atraumatic, tissue-sparing and easy to use, potentially enabling clinicians to intervene at earlier stages of sinus disease. The company seeks to provide improved options for the 20 percent of sinusitis patients whose disease is not resolved with drug therapy.

###